2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
ReposiTrak, Inc. entered into a three-year executive employment agreement with CFO and Principal Accounting Officer John R. Merrill, effective August 18, 2026. The agreement sets a $325,000 base salary and grants 75,000 restricted shares, which matters to shareholders as a compensation and retention arrangement for the finance chief.
Base salary of $325,000, retroactive to May 16, 2026; target bonus 60% of base salary
Grant of 75,000 shares of restricted common stock vesting in four equal annual installments
Severance on termination without Cause or resignation for Good Reason: nine months of base salary plus COBRA coverage support, with double-trigger protection after a Change in Control
Foxx Development Holdings Inc. disclosed that Chief Technology Officer James Liao resigned effective August 14, 2026, from the parent company and from its operating subsidiary, Foxx Development Inc. The company said he resigned for personal reasons and not because of any disagreement over operations, policies or practices.
James Liao resigned as Chief Technology Officer effective August 14, 2026
He also resigned as Chief Technology Officer of operating subsidiary Foxx Development Inc.
The company says the resignation was for personal reasons, not a disagreement with the company
The filing was signed by CFO Joy Yi Hua on August 18, 2026
Legence Corp. increased its board from six to seven directors and appointed Robert Crisci as a Class II director effective August 18, 2026. Crisci also joins the Audit Committee and the Nomination and Corporate Governance Committee, and the board determined he is independent under Nasdaq rules.
Crisci, age 51, previously served as CFO of Lineage, Inc. from 2023 until retiring in November 2025, and as CFO of Roper Technologies from 2017 until January 2023.
He receives standard non-management director pay: an $85,000 annual cash retainer and restricted stock units valued at approximately $150,000 at grant.
His initial term expires at the 2027 annual meeting of shareholders, and he has signed the standard indemnification agreement (Exhibit 10.1).
Cocrystal Pharma's Board of Directors appointed Carol L. Brosgart as a director on August 12, 2026, effective immediately. The filing states there are no related party transactions or family relationships that require disclosure, and it does not describe her background or committee roles.
Board appointed Carol L. Brosgart as a director on August 12, 2026, effective immediately
Filing states no arrangements or understandings tied to her selection and no related party transactions requiring disclosure under Item 404(a)
Report signed by CFO James Martin on August 18, 2026
Blue Water Acquisition Corp. IV, a blank-check company, appointed Nadab Akhtar to its board of directors effective August 12, 2026, as a Class I director. The board determined he is independent and placed him on its audit, compensation, and nominating and corporate governance committees.
Appointment effective August 12, 2026, made by Blue Water Acquisition IV LLC, sole holder of Class B ordinary shares.
Akhtar is Founder and Managing Partner of Excite Capital and Co-Founder and CEO of Project LightShift.
He joins the audit, compensation, and nominating and corporate governance committees.
The filing states no family relationships with directors or officers and no arrangement under which he was appointed.
Brighthouse Financial appointed Deputy Chief Accounting Officer Richard A. Cook as Chief Accounting Officer, succeeding Melissa B. Pavlovich, who is leaving the company for a new opportunity. The filing says her departure is not related to financial statements, disclosures, or accounting principles and practices.
Richard A. Cook becomes Chief Accounting Officer effective September 3, 2026, succeeding Melissa B. Pavlovich.
Pavlovich informed the company on August 12, 2026 of her resignation; her last day is September 2, 2026.
Cook's offer letter sets an annual base salary of $425,000, a target short-term incentive of 60% of base salary, and an LTI target valued at $219,500.
Kennametal appointed Dawne Hickton and Richard Harshman as directors, effective September 1, 2026, with election proposed at the October 2026 annual shareholder meeting. The filing describes board additions rather than financial results, operations or a change in management.
Richard J. Harshman, 70, is the retired Executive Chairman and former CEO of ATI Inc.
Dawne Hickton, 68, is Chair and CEO of Cumberland Additive, Inc. and formerly led Jacobs' Critical Mission Solutions business.
Neither director will immediately serve on a Board committee; both are expected to join committees in the coming months.
Both will sign indemnification agreements with the company, and the filing reports no related-party transactions.
Robert Eckert, a Class III director who had served on Levi Strauss & Co.'s board since 2010, retired on August 14, 2026, after reaching the company's mandatory retirement age of 72. The board reduced its size to ten directors, and Joshua Prime was named chair of the Nominating, Governance and Corporate Citizenship Committee.
Robert Eckert retired from the board on August 14, 2026, having reached the mandatory retirement age; he had served since 2010.
Eckert had most recently been board chair until April 2026, and chair of the NGCC Committee.
Joshua Prime was appointed to the NGCC Committee and named its chair, effective upon Eckert's retirement.
The company said the retirement is not the result of any disagreement with the company on operations, policies or practices.
nVent Electric said Randolph A. Wacker, who had announced plans to retire effective September 1, 2026, will instead stay on as Senior Vice President and Chief Accounting Officer. The Board appointed him to that role on August 14, effective September 1, 2026. For shareholders, this keeps the company's principal accounting officer in place and removes a planned leadership transition from the picture.
Randolph A. Wacker had previously announced plans to retire effective September 1, 2026, disclosed in a June 17, 2026 Form 8-K.
The Board appointed Wacker as Senior Vice President and Chief Accounting Officer on August 14, effective September 1, 2026.
Tyler Krutzig will continue as Assistant Corporate Controller.
The filing was signed by CFO Gary L. Corona on August 18, 2026.
Halozyme Therapeutics elected Dannielle Appelhans to its Board of Directors on August 14, 2026, in the class with terms ending at the 2028 annual meeting. She was not initially assigned to any Board committee, and the filing says she will receive compensation under the standard non-employee director program.
Board election effective August 14, 2026; term ends at the 2028 annual meeting of stockholders
Not initially assigned to any Board committee
Compensation follows the non-employee director program (cash retainers, restricted stock and stock options)
Filing states no arrangements or related person transactions with the company
Rhinebeck Bancorp, Inc. appointed Suzanne Rhulen Loughlin to its Board of Directors effective immediately on August 18, 2026, and placed her on the Compensation Committee and the Governance and Nominating Committee. Loughlin previously served as a director of Rhinebeck Bank, the company's wholly-owned subsidiary, from 2011 until December 17, 2025, and is now returning to the board at the holding company level. The filing reports no financial results and describes a board appointment rather than a change in operations.
Suzanne Rhulen Loughlin appointed to the Board of Directors effective August 18, 2026
Appointed to the Compensation Committee and the Governance and Nominating Committee
Loughlin has been a director of Rhinebeck Bank, the wholly-owned subsidiary, since 2011, with a break from 2019 until December 17, 2025
Filing states no arrangements with other persons for her selection and no related-party disclosure under Item 404(a)
York Water's Board appointed David M. Velazquez, former President and CEO of PECO Energy, as a new independent director, effective September 1, 2026. The filing says he has more than 40 years of energy and utility industry experience and will sit on the Board's Executive Committee.
Appointed at the Board's August 17, 2026 regularly scheduled meeting, effective September 1, 2026
Term expires at the 2027 Annual Meeting of Shareholders
Will be assigned to the Board's Executive Committee
Filing states no related-party transaction requiring disclosure under Item 404(a) of Regulation S-K
Catalyst Bank entered into a new employment agreement with President and CEO Joseph B. Zanco on August 17, 2026, running through August 17, 2029. The filing sets a $350,000 base salary and includes enhanced severance and change-in-control terms, so shareholders should note the potential cost if his employment ends.
New agreement term runs August 17, 2026 to August 17, 2029, unless renewed or extended.
Base salary of $350,000, which the board may increase at its discretion.
Severance on involuntary termination: 12 months of base salary; 36 months if terminated within 30 days after a change in control.
Inspired Entertainment said its General Counsel and EVP Simona Camilleri will step down effective September 7, 2026, and that Carys Damon, the current Company Secretary, will take on the General Counsel role on that date while keeping her Company Secretary title. The change is an executive handover, with no financial results or guidance included in the filing, so its impact on shareholders appears limited.
Simona Camilleri's role as EVP and General Counsel ends effective September 7, 2026; she remains on garden leave until December 31, 2026
Carys Damon, Company Secretary since July 2024 and a Company employee since 2012, becomes EVP and General Counsel effective September 7, 2026
Ms. Damon will be responsible for the Company's legal and compliance functions
Xylem said CFO William Grogan will resign effective August 31, 2026 to pursue another opportunity, and Andrea van der Berg, currently SVP Finance for the Water Infrastructure segment, will become CFO on September 1, 2026. Xylem also reaffirmed its third-quarter and full-year 2026 guidance issued July 28, 2026, which matters to shareholders because it signals no change to the outlook alongside the finance leadership change.
Grogan remains employed through September 13, 2026 to support the transition.
Van der Berg's annual base salary is $675,000, with an AIP target of 80% of base salary.
Van der Berg receives a one-time 2026 LTIP award with a grant date value of $787,500, and a new LTIP target award of $1,750,000.
Xylem reaffirmed its third-quarter and full-year 2026 guidance issued July 28, 2026.
Privia Health Group's board elected Opella Ernest, M.D., a former HCSC executive, as a Class III director effective September 1, 2026, and named her to the Compliance Committee. The change adds a director to the board and carries a $200,000 grant-date value equity award, but the filing does not describe any financial results or operational impact.
Dr. Ernest was elected by the board on August 12, 2026, effective September 1, 2026.
She was appointed to the Compliance Committee effective September 1, 2026.
Non-employee director pay includes an annual cash retainer and restricted stock units with a $200,000 grant-date fair market value.
Dr. Ernest is currently President, HCSC Markets at Health Care Service Corporation, a role held since 2023.
GE HealthCare appointed William K. Grogan, currently executive vice president and CFO of Xylem Inc., as Chief Financial Officer effective September 14, 2026, succeeding interim CFO George Newcomb, who will remain Controller and Chief Accounting Officer. The filing sets out his pay package, including a $900,000 base salary, a 100% target bonus, and sign-on awards to offset compensation forfeited at Xylem, which matters to shareholders as it defines the company's new top finance executive and its compensation commitments.
Grogan, age 48, has been Xylem's EVP and CFO since October 2023 and was IDEX Corporation's CFO from January 2017 to September 2023.
Offer letter: $900,000 base salary, target annual bonus of 100% of salary, and a 2026 annual LTI award with a $3,300,000 target grant date value.
Sign-on payments include $550,000 in cash and a $4,000,000 RSU award, with cash repayment required if he resigns within two years.
Newcomb ceases as interim CFO on September 14, 2026, and continues as Controller and Chief Accounting Officer.
Entera Bio appointed Dr. Riccardo Paolo Camisasca as Chief Medical Officer effective August 18, 2026. The company said the hire comes ahead of the planned Phase 3 initiation of its EB613 oral osteoporosis candidate, which it describes as its most advanced product candidate.
Dr. Riccardo Paolo Camisasca appointed Chief Medical Officer, effective immediately on August 18, 2026
Dr. Camisasca has more than 30 years of experience, most recently as Global Head of Research & Development at Sumitomo Pharma Switzerland
Company plans to initiate a Phase 3 program for EB613, its oral PTH(1-34) tablet candidate for osteoporosis
Nano Dimension appointed Nadav Kidron as an independent director on August 16, 2026, effective immediately, with seats on the Audit and Compensation Committees. In a separate Regulation FD disclosure, the company said the 30-day exclusivity period under a non-binding term sheet with Infinite Epigenetics expired on July 15, 2026, and no definitive agreement has been reached.
Nadav Kidron appointed to the Board as a Class II director effective August 16, 2026, serving until the 2026 annual meeting
Kidron to serve on the Audit Committee and Compensation Committee; Board determined he is independent under Nasdaq rules
Exclusivity under the non-binding term sheet with Infinite Epigenetics, Inc. expired July 15, 2026
As of the filing date, the parties have not agreed on terms of a definitive agreement
Copart appointed David J. Berger as a director effective August 13, 2026, with a term running to its 2026 annual meeting. Berger is a senior partner at Wilson Sonsini Goodrich & Rosati, which the company uses as outside corporate counsel, and the company expects to use that firm for routine legal work going forward, with fees it considers not material.
Berger joined the board effective August 13, 2026; his initial term expires at the 2026 annual meeting of stockholders
Berger is a senior partner at Wilson Sonsini, Copart's outside corporate counsel, and the company expects routine engagements with the firm; fees for fiscal 2027 are expected to be not material
Company says no related party transactions requiring disclosure under Item 404(a) for fiscal year ended July 31, 2026
Announced in a press release dated August 17, 2026; Berger will join the outside director compensation program and has signed the standard indemnification agreement
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.